Search the Newsreel

Cardiff Loss Narrows In Q2; Directs Resources To Phase 3 For Onvansertib In Q1 '27

(RTTNews) - Cardiff Oncology, Inc. (CRDF) a clinical-stage oncology company, reported second quarter results, reflecting a narrower loss primarily driven by lower operating expenses. The company in particular noted reduced Research and Development (R&D) expenses following the completion of clinical trials and lesser preclinical …

William Blair Downgrades Cardiff Oncology to Market Perform From Outperform

William Blair has downgraded Cardiff Oncology (CRDF) from an "Outperform" rating to "Market Perform." This comes shortly after Cardiff Oncology reported its earnings results for the second quarter and six months ended June 30, 2026. The company is a clinical-stage biotechnology firm focused on …

William Blair downgrades Cardiff Oncology stock rating on rights uncertainty

William Blair has downgraded Cardiff Oncology (NASDAQ: CRDF) from Outperform to Market Perform, citing material deterioration in company fundamentals and uncertainty surrounding onvansertib rights. This downgrade follows Cardiff’s Q2 financial results and business update, with the stock already down 63% year-to-date and the company …

Cardiff Oncology (NASDAQ: CRDF) cuts R&D spend but flags going concern risk

Cardiff Oncology reported a Q2 2026 net loss of $9.2 million and a six-month operating cash outflow of $24.1 million, reducing R&D expenses by cutting clinical trials and preclinical work. The company raised $10.1 million in a direct offering but issued a "going concern" …

Cardiff Oncology earnings missed by $0.02, revenue topped estimates

Cardiff Oncology: Q2 Earnings Snapshot

Cardiff Oncology, Inc. (CRDF) reported a Q2 loss of $9.2 million, or 14 cents per share, surpassing Wall Street expectations that predicted a loss of 17 cents per share. The company achieved revenue of $104,000, which met Street forecasts. This financial summary was generated …

Cardiff Oncology (NASDAQ:CRDF) Releases Earnings Results, Misses Expectations By $0.02 EPS

Cardiff Oncology (NASDAQ:CRDF) reported a quarterly loss of $0.14 per share, missing analyst expectations by $0.02, despite revenue of $0.10 million surpassing the consensus estimate. The company's shares are trading under pressure, well below moving averages, and analysts generally hold a "Hold" rating. Despite …

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology announced its second quarter 2026 financial results and provided a business update, highlighting positive Phase 2 data for its drug onvansertib in first-line RAS-mutated metastatic colorectal cancer. The company plans to initiate a registrational Phase 3 trial in Q1 2027, pending additional …

Cardiff Oncology Inc (CRDF) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cardiff Oncology Inc (CRDF) has an earnings forecast score of 7.25, ranking 296 out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $10.00, with a high of $19.00 and a low of $3.50, based on …

BlackRock, Inc. Slashes Cardiff Oncology (CRDF) Stake by 78.3%

BlackRock, Inc. significantly reduced its stake in Cardiff Oncology Inc. (CRDF) by 78.32%, selling over 3.1 million shares. This move reflects BlackRock's shift away from speculative biotech ventures towards more established technology and financial services companies. Cardiff Oncology faces significant financial challenges, including unprofitability …

Cardiff Oncology Inc (CRDF) Risk Assessment: Volatility, Financial Risk & Investment Risk

Cardiff Oncology Inc (CRDF) currently has a risk assessment score of 3.90, ranking 107 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 1.35 indicates higher volatility compared to the S&P 500. The article details various risk metrics …

Cardiff Oncology (CRDF) Expected to Post Quarterly Earnings on Tuesday

BlackRock (CRDF holder) discloses 863,259 Cardiff Oncology shares in 13G/A

BlackRock, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 863,259 shares of Cardiff Oncology, Inc. common stock, which represents a 1.3% stake in the company. BlackRock exercises sole voting and dispositive power over these shares, and the filing clarifies that no …

CRDF|Cardiff Oncology Inc|Price:0.827|Chg%:-0.011

This article provides a detailed financial overview of Cardiff Oncology Inc. (CRDF), including its stock performance, key financial indicators, and historical data from income statements, balance sheets, and cash flow statements. It highlights the company's latest earnings report and future forecasts, offering investors comprehensive …

Cardiff Oncology, Inc. Revenue Breakdown – NASDAQ:CRDF

Cardiff Oncology, Inc. (NASDAQ: CRDF) generated $593,000 USD in revenue last year from its top-performing segment, Novel Therapies for Cancers, a decrease from $683,000 USD in the prior year. All of the company's revenue last year came from the United States.

Cardiff Oncology Inc (CRDF) Valuation: PE, PB & Fair Value Analysis

Cardiff Oncology Inc (CRDF) currently holds a valuation score of 6.15, placing it 356th out of 386 in the Biotechnology & Medical Research industry. Its P/E ratio stands at -1.24, which is significantly lower than its recent high and higher than its recent low. …

Cardiff Oncology Inc (CRDF) Institutional Confidence

Cardiff Oncology Inc (CRDF) has an institutional shareholding score of 3.00, placing it 192nd in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 35.32%, a significant decrease of 33.21% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 0.15% of shares …

Cardiff Oncology Inc (CRDF) Financial Health: Profitability & Balance Sheet Analysis

Cardiff Oncology Inc (CRDF) currently holds a financial score of 5.79, ranking 327 out of 386 in the Biotechnology & Medical Research industry, indicating stable financial health but low operating efficiency. The company's latest quarterly revenue was $41.00K, marking a 62.39% year-over-year decrease, while …

Cardiff Oncology Inc (CRDF) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cardiff Oncology Inc (CRDF), highlighting its current price momentum score of 5.65 and its trading range between support at 0.61 and resistance at 1.24. It details various technical indicators like MACD, RSI, and moving averages, which predominantly …

CRDF|Cardiff Oncology Inc|Price:0.845|

Cardiff Oncology Inc. is a clinical-stage biotechnology company focused on developing novel therapies for various cancers using PLK1 inhibition. Their lead drug candidate, Onvansertib, is in clinical trials for indications like RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and …

TradingKey

This page provides the quarterly and annual income statement data for Cardiff Oncology Inc. (CRDF), detailing key financial metrics such as total revenue, operating expenses, net income, and earnings per share over several fiscal periods. It also includes an overview of the company's current …

Friday 7/17 Insider Buying Report: CRDF, FIS

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Cardiff Oncology, a filing with the …

Cardiff Oncology (CRDF) Proxy filing Summary

Cardiff Oncology (CRDF) has scheduled its annual meeting for June 11, 2026, where shareholders will vote on four key proposals: the election of six directors, the ratification of BDO USA, P.C. as auditor, an amendment to increase shares under the 2021 Equity Incentive Plan, …

Form 4 Cardiff Oncology Inc For: 16 July By Investing.com

This article provides a Form 4 filing for Cardiff Oncology Inc. for July 16, 2026. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's …

Cardiff Oncology (CRDF) CEO adds common shares and new warrants stake

Cardiff Oncology (CRDF) CEO Mani Mohindru purchased 34,364 common shares on July 14, 2026, at $1.455 per share and acquired an equal number of common stock purchase warrants. These transactions increased her direct holdings to 59,067 common shares and 34,364 warrants. The warrants have …

Cardiff Oncology (CRDF) director buys 687,285 shares and warrants

Cardiff Oncology, Inc. director Gary W. Pace reported open-market purchases of 687,285 shares of common stock at $1.455 per share and an equal number of common stock purchase warrants with an exercise price of $1.33 per share, dated July 14, 2026. Following these transactions, …

Cardiff Oncology Raises $10M for Onvansertib Regulatory Push

Cardiff Oncology (CRDF) has raised $10 million in a registered direct offering to support regulatory discussions for its lead drug, onvansertib. The drug, an oral PLK1 inhibitor, showed promising Phase II results for RAS-mutated metastatic colorectal cancer, achieving a 72.2% objective response rate. This …

Cardiff Oncology (NASDAQ: CRDF) prices $10.05M share and warrant financing

Cardiff Oncology Inc. (NASDAQ: CRDF) has priced a public offering to raise $10.05 million through the sale of common stock and accompanying warrants. The offering includes 9,293,078 shares of common stock and warrants to purchase an equal number of shares, with proceeds designated for …

Cardiff Oncology (Nasdaq: CRDF) closes $10.05M direct offering

Cardiff Oncology (Nasdaq: CRDF) has successfully closed a direct offering totaling approximately $10.05 million. The offering involved the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 per share and warrant, with certain officers and directors also purchasing shares at a …

Cardiff Oncology Raises $10.05 Million in Registered Offering; Engages H.C. Wainwright

Cardiff Oncology successfully completed a registered equity financing, raising approximately $10.05 million in gross proceeds through the sale of shares and warrants to institutional investors and insiders. The company also engaged H.C. Wainwright as its exclusive placement agent for the offering. Proceeds from this …

Cardiff Oncology to Raise $10 Million in Share, Warrant Sale

Cardiff Oncology plans to raise $10 million through the sale of shares and warrants to Armistice Capital Master Fund. The company will sell 10 million shares of common stock and warrants to purchase up to 10 million shares at a price of $1.00 per …

Cardiff Oncology Seeks $10M as Some Officers and Directors Agree to Buy Shares

Cardiff Oncology (Nasdaq: CRDF) announced a registered direct offering to raise approximately $10 million by selling 8,571,429 common shares and accompanying warrants at $1.05 per share. Separately, certain officers and directors will purchase 731,707 shares and warrants at $1.435 per share. The warrants have …

Cardiff Oncology prices $10M registered direct offering

Cardiff Oncology (NASDAQ:CRDF) announced a $10 million registered direct offering, selling over 8.5 million shares and accompanying warrants at $1.05 per share and warrant. Company officers and directors are participating in the offering. The biotech firm plans to use the net proceeds for working …